Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study

Tocilizumab prevents clinical worsening of chronic antibody-mediated rejection (CAMR) of kidney transplant recipients. Optimization of this treatment is necessary. We identified the determinants of early tocilizumab exposure (within the first three months) and investigated the relationship between e...

Descripción completa

Detalles Bibliográficos
Autores principales: Arrivé, Capucine, Jacquet, Marvin, Gautier-Veyret, Elodie, Jouve, Thomas, Noble, Johan, Lombardo, Dorothée, Rostaing, Lionel, Stanke-Labesque, Françoise
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672331/
https://www.ncbi.nlm.nih.gov/pubmed/38002753
http://dx.doi.org/10.3390/jcm12227141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672331/
https://www.ncbi.nlm.nih.gov/pubmed/38002753
http://dx.doi.org/10.3390/jcm12227141

Ejemplares similares